LGND Relative Valuation
LGND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LGND is overvalued; if below, it's undervalued.
Historical Valuation
Ligand Pharmaceuticals Inc (LGND) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.24 is considered Undervalued compared with the five-year average of -10.07. The fair price of Ligand Pharmaceuticals Inc (LGND) is between 153.08 to 186.33 according to relative valuation methord. Compared to the current price of 124.30 USD , Ligand Pharmaceuticals Inc is Undervalued By 18.8%.
Relative Value
Fair Zone
153.08-186.33
Current Price：124.30
18.8%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.01
P/B
Median3y
2.04
Median5y
2.27
2.08
FCF Yield
Median3y
5.59
Median5y
4.51
Competitors Valuation Multiple
The average P/S ratio for LGND's competitors is 38.35, providing a benchmark for relative valuation. Ligand Pharmaceuticals Inc Corp (LGND) exhibits a P/S ratio of 12.76, which is -66.72% above the industry average. Given its robust revenue growth of 46.34%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Ligand Pharmaceuticals Inc (LGND) currently overvalued or undervalued?
What is Ligand Pharmaceuticals Inc (LGND) fair value?
How does LGND's valuation metrics compare to the industry average?
What is the current P/B ratio for Ligand Pharmaceuticals Inc (LGND) as of Jul 17 2025?
What is the current FCF Yield for Ligand Pharmaceuticals Inc (LGND) as of Jul 17 2025?
What is the current Forward P/E ratio for Ligand Pharmaceuticals Inc (LGND) as of Jul 17 2025?